Login
Companies $ELDN
$2.01 +$0.04 (2.23%) After hours
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc.

eledon.com

What Do They Do?

Develops tegoprubart, an antibody therapy intended to prevent rejection in organ transplant recipients and treat amyotrophic lateral sclerosis in people living with the disease.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +77% (Loss)
vs −$17.5M in Q3 FY2025

IgA nephropathy program The older report said work on the IgA nephropathy program was deprioritized; the latest describes the program as discontinued.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support